Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX69
|
| gptkbp:CASNumber |
1403254-99-8
|
| gptkbp:chemicalFormula |
C34H44N6O4
|
| gptkbp:developer |
gptkb:Epizyme,_Inc.
|
| gptkbp:genericName |
gptkb:tazemetostat
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tazverik
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:mechanismOfAction |
EZH2 inhibitor
|
| gptkbp:molecularWeight |
600.76 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting constipation fatigue cough decreased appetite |
| gptkbp:usedFor |
epithelioid sarcoma
follicular lymphoma |
| gptkbp:bfsParent |
gptkb:EPZ-6438
gptkb:tazemetostat gptkb:Epizyme |
| gptkbp:bfsLayer |
8
|